PREGLED ANTIVIRUSNIH LEKOVA PROTIV SARS-CoV-2 ZA LEČENJE COVID-19
LEKOVI PROTIV SARS-CoV-2
Sažetak
Novi koronavirus SARS-CoV-2 brzo se proširio širom sveta uzrokujući globalnu pandemiju. Svojstvena svojstva virusa čine ga potencijalno fatalnim, jer težina bolesti COVID-19 varira među osobama sa trenutno nepoznatom pozadinom. Svetska zajednica je stoga očajnički traga za novim antivirusnim lekovima protiv SARS-CoV-2. U ovom radu fokusiramo se na makromolekularne ciljeve prisutne na virusu SARS-CoV-2 kao potencijalne ciljeve za antivirusne lekove. U nastavku nudimo kratku prezentaciju lekova ili kandidata za lekove koji deluju direktno na životni ciklus virusa i imaju obećavajuće efekte u terapiji COVID-19.
Reference
Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et al. Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Corona-virus with a High Genetic Barrier to Resistance. J Virol 2019;93(24):e01348-19. [CrossRef] [PubMed]
Baranovich T, Wong S-S, Armstrong J, Marjuki H, Webby RJ, Webster RG, et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013;87(7):3741-51. [CrossRef] [PubMed]
Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014;107: 84-94. [CrossRef] [PubMed]
Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9(1):221-36. [CrossRef] [PubMed]
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci 2020;6(5):672-83. [CrossRef] [PubMed]
European Medicines Agency. Kaletra SmPC. EMA, “cited 2020 May 24”; Available from: URL: https://www.ema.europa.eu/en/documents/product-information/kaletra-epar-product-information_en.pdf
FDA approves first treatment for COVID-19. FDA (news release), 2020 October 22 “cited 2020 October 23”; Available from: URL: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
Ferner RE, Aronson JK. Remdesivir in COVID-19. BMJ 2020;369:m1610. [CrossRef] [PubMed]
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100(2):446-54. [CrossRef] [PubMed]
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93(7):449-63. [CrossRef] [PubMed]
Ghosh AK, Brindisi M, Shahabi D, Chapman ME, Mesecar AD. Drug Development and Medicinal Che-mistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem 2020;15(11):907-32. [CrossRef] [PubMed]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181(2): 271-80.e8. [CrossRef] [PubMed]
Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci 2017;114(2):206-14. [CrossRef] [PubMed]
Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med 2020; 1(1):105-113.e4. [CrossRef] [PubMed]
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloro-quine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6(1):16. [CrossRef] [PubMed]
Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. SARS-CoV-2 is sensitive to type I interferon pretreatment.J Virol 2020;94(23):e01410-20. [CrossRef] [PubMed]
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 2020;395(10224):565-74. [CrossRef] [PubMed]
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem 2020;21(5): 730-8. [CrossRef] [PubMed]
Pharmaceutical and Food Safety Bureau. Report on the Deliberation results: Avigan Tablet 200 mg. Ministry of Health, Labour and Welfare Japan, 2014 March 4 “cited 2020 May 24”; Available from: URL: https://www.pmda.go.jp/files/000210319.pdf
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18(1):41-58. [CrossRef] [PubMed]
Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. Current pharmacological treat-ments for COVID-19: What’s next? Br J Pharmacol 2020;177(21):4813-24. [CrossRef] [PubMed]
Shalhoub S. Interferon beta-1b for COVID-19. The Lancet 2020;395(10238):1670-1. [CrossRef] [PubMed]
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple corona-viruses in mice. Sci Transl Med 2020; 12(541): eabb5883. [CrossRef] [PubMed]
Sissoko D, Laouenan C, Folkesson E, M’Lebing A-B, Beavogui A-H, Baize S, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med 2016;13(3): e1001967. [CrossRef] [PubMed]
Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, et al. The anti-influenza virus drug, arbidol is an efficient inhi-bitor of SARS-CoV-2 in vitro. Cell Discov 2020;6(1):1-5. [CrossRef] [PubMed]
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a rando-mised, double-blind, placebo-controlled, multicentre trial. The Lancet 2020;395(10236):1569-78. [CrossRef] [PubMed]
Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respire-tory disease in China. Nature 2020;579(7798):265-9. [CrossRef] [PubMed]
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367(6485):1444-8. [CrossRef] [PubMed]
Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 2020;87:59-73. [CrossRef] [PubMed]
Zhou D, Dai S-M, Tong Q. COVID-19: a recommenda-tion to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020;75(7):1667-70. [CrossRef] [PubMed]